Rising Penn star Saar Gill gets funding for a next-gen CAR-T startup, adding a new weapon to the mix
Earlier this month, the University of Pennsylvania’s Saar Gill turned up at ASCO to present new data demonstrating that a combination of Imbruvica with Novartis’ next-gen CAR-T CTL119 proved very effective in treating particularly lethal cases of chronic lymphocytic leukemia, wiping out all signs of the disease in 8 of 9 treatment-resistant patients enrolled in an exploratory study.
But Gill’s been particularly busy on the CAR-T front, and not just in new research work. He’s also been enlisting some marquee investors on a new startup project that will aim at making a major new advance in the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.